Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have recently been recommended as a
foundational therapy for patients with heart failure (HF) and reduced ejection fraction …

In the last years, major progress occurred in heart failure (HF) management. Quadruple
therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst …

This clinical consensus statement reviews the use of inotropic support in patients with
advanced heart failure. The current guidelines only support use of inotropes in the setting of …

Heart failure (HF) is a major cause of mortality, hospitalizations, and reduced quality of life
and a major burden for the healthcare system. The number of patients that progress to an …

Major changes have occurred in these last years in heart failure (HF) management.
Landmark trials and the 2021 European Society of Cardiology guidelines for the diagnosis …

Aim Patients with heart failure with reduced ejection fraction and low systolic blood pressure
(SBP) have high mortality, hospitalizations, and poorly tolerate evidence-based medical …

Background Following the availability of new drugs for chronic heart failure (HF) with
reduced ejection fraction (HFrEF), we sought to provide an updated and comparative …

The introduction of multiple new pharmacological agents over the past three decades in the
field of heart failure with reduced ejection fraction (HFrEF) has led to reduced rates of …

Echocardiography represents an essential tool for imagers and clinical cardiologists in the
management of patients with heart failure. Advanced heart failure (AdHF) is a more severe …

Background Few data are available regarding changes in mitral regurgitation (MR) severity
with guideline-recommended medical therapy (GRMT) in heart failure (HF). Our aim was to …